A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1538-1545

  Holmes, Tim D ^a   El Sherbiny, Yasser M ^a   Davison, Adam ^a   Clough, Sally L ^a   Blair, G Eric ^b   Cook, Graham P ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D;

ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; EWING SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTICELLULAR SPHEROID; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; TARGET CELL; TUMOR SPHEROID;

CELL LINE, TUMOR; CELL MEMBRANE; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENETIC PREDISPOSITION TO DISEASE; HELA CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SARCOMA, EWING'S; SPHEROIDS, CELLULAR; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 79251577713     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000951     Document Type: Article

References (46)

1. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
2. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502.
3. Moretta, L., and A. Moretta. 2004. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 23: 255-259. (Pubitemid 38294490)
4. Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678. (Pubitemid 16119452)
5. Lanier, L. L. 2005. Missing self, NK cells, and The White Album. J. Immunol. 174: 6565.
6. Ljunggren, H. G., and K. Kärre. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11: 237-244.
7. Peterson, M. E., and E. O. Long. 2008. Inhibitory receptor signaling via tyrosine phosphorylation of the adaptor Crk. Immunity 29: 578-588.
8. Kim, H. S., A. Das, C. C. Gross, Y. T. Bryceson, and E. O. Long. 2010. Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 32: 175-186.
9. Bryceson, Y. T., H. G. Ljunggren, and E. O. Long. 2009. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 114: 2657-2666.
10. Arvand, A., and C. T. Denny. 2001. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20: 5747-5754.
11. Verhoeven, D. H., A. S. de Hooge, E. C. Mooiman, S. J. Santos, M. M. ten Dam, H. Gelderblom, C. J. Melief, P. C. Hogendoorn, R. M. Egeler, M. J. van Tol, et al. 2008. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol. Immunol. 45: 3917-3925.
12. Myatt, S. S., C. P. Redfern, and S. A. Burchill. 2005. p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin. Cancer Res. 11: 3136-3148.
13. Meade, J. L., E. A. de Wynter, P. Brett, S. M. Sharif, C. G. Woods, A. F. Markham, and G. P. Cook. 2006. A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity. Blood 107: 3665-3668.
14. Betts, M. R., J. M. Brenchley, D. A. Price, S. C. De Rosa, D. C. Douek, M. Roederer, and R. A. Koup. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78.
15. Meade, J. L., E. B. Wilson, T. D. Holmes, E. A. de Wynter, P. Brett, L. Straszynski, P. A. Ballard, J. A. Trapani, M. F. McDermott, and G. P. Cook. 2009. Proteolytic activation of the cytotoxic phenotype during human NK cell development. J. Immunol. 183: 803-813.
16. Pende, D., S. Parolini, A. Pessino, S. Sivori, R. Augugliaro, L. Morelli, E. Marcenaro, L. Accame, A. Malaspina, R. Biassoni, et al. 1999. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190: 1505-1516.
17. Vitale, M., C. Bottino, S. Sivori, L. Sanseverino, R. Castriconi, E. Marcenaro, R. Augugliaro, L. Moretta, and A. Moretta. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187: 2065-2072.
18. Castriconi, R., A. Dondero, F. Negri, F. Bellora, P. Nozza, B. Carnemolla, A. Raso, L. Moretta, A. Moretta, and C. Bottino. 2007. Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur. J. Immunol. 37: 3190-3196.
19. Lawlor, E. R., C. Scheel, J. Irving, and P. H. Sorensen. 2002. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 21: 307-318.
20. Kang, H. G., J. M. Jenabi, J. Zhang, N. Keshelava, H. Shimada, W. A. May, T. Ng, C. P. Reynolds, T. J. Triche, and P. H. Sorensen. 2007. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 67: 3094-3105.
21. Peaper, D. R., and P. Cresswell. 2008. Regulation of MHC class I assembly and peptide binding. Annu. Rev. Cell Dev. Biol. 24: 343-368.
22. Piontek, G. E., K. Taniguchi, H. G. Ljunggren, A. Grönberg, R. Kiessling, G. Klein, and K. Kärre. 1985. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J. Immunol. 135: 4281-4288.
23. Pende, D., L. Accame, L. Pareti, A. Mazzocchi, A. Moretta, G. Parmiani, and L. Moretta. 1998. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur. J. Immunol. 28: 2384-2394.
24. Ohlén, C., M. T. Bejarano, A. Grönberg, S. Torsteinsdottir, L. Franksson, H. G. Ljunggren, E. Klein, G. Klein, and K. Kärre. 1989. Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2. J. Immunol. 142: 3336-3341.
25. Shimizu, Y., and R. DeMars. 1989. Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur. J. Immunol. 19: 447-451.
26. Storkus, W. J., J. Alexander, J. A. Payne, J. R. Dawson, and P. Cresswell. 1989. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364.
27. Storkus, W. J., D. N. Howell, R. D. Salter, J. R. Dawson, and P. Cresswell. 1987. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol. 138: 1657-1659.
28. Harel-Bellan, A., A. Quillet, C. Marchiol, R. DeMars, T. Tursz, and D. Fradelizi. 1986. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc. Natl. Acad. Sci. USA 83: 5688-5692.
29. Borrego, F., M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187: 813-818.
30. Stam, N. J., W. M. Kast, A. C. Voordouw, L. B. Pastoors, F. A. van der Hoeven, C. J. Melief, and H. L. Ploegh. 1989. Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells. J. Immunol. 142: 4113-4117.
31. Peña, J., C. Alonso, R. Solana, R. Serrano, J. Carracedo, and R. Ramirez. 1990. Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur. J. Immunol. 20: 2445-2448.
32. Parham, P. 2005. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5: 201-214.
33. Fadda, L., G. Borhis, P. Ahmed, K. Cheent, S. V. Pageon, A. Cazaly, S. Stathopoulos, D. Middleton, A. Mulder, F. H. Claas, et al. Peptide antagonism as a mechanism for NK cell activation. Proc. Natl. Acad. Sci. USA 107: 10160-10165.
34. Almeida, C. R., and D. M. Davis. 2006. Segregation of HLA-C from ICAM-1 at NK cell immune synapses is controlled by its cell surface density. J. Immunol. 177: 6904-6910.
35. Joncker, N. T., N. C. Fernandez, E. Treiner, E. Vivier, and D. H. Raulet. 2009. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J. Immunol. 182: 4572-4580.
36. Waldhauer, I., and A. Steinle. 2008. NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943.
37. Oppenheim, D. E., S. J. Roberts, S. L. Clarke, R. Filler, J. M. Lewis, R. E. Tigelaar, M. Girardi, and A. C. Hayday. 2005. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6: 928-937.
38. Castriconi, R., C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100: 4120-4125.
39. Doubrovina, E. S., M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171: 6891-6899.
40. Gallimore, A. M., and A. K. Simon. 2008. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27: 5886-5893.
41. Liu, C., S. Yu, J. Kappes, J. Wang, W. E. Grizzle, K. R. Zinn, and H. G. Zhang. 2007. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109: 4336-4342.
42. Berghuis, D., A. S. de Hooge, S. J. Santos, D. Horst, E. J. Wiertz, M. C. van Eggermond, P. J. van den Elsen, A. H. Taminiau, L. Ottaviano, K. L. Schaefer, et al. 2009. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J. Pathol. 218: 222-231.
43. Campoli, M., and S. Ferrone. 2008. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27: 5869-5885.
44. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
45. Teng, M.W., J. B. Swann, C. M. Koebel, R. D. Schreiber, and M. J. Smyth. 2008. Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84: 988-993.
46. Diefenbach, A., E. R. Jensen, A.M. Jamieson, and D. H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.